Planning a biotech year means planning around conferences, and the calendar has a rhythm once you learn it. It opens with a bang in January, builds through a dense spring of scientific data and partnering, quiets over the summer, and closes with a strong autumn and a December finale. Here is the year laid out month by month, with the marquee events and what each part of the calendar is actually good for. Dates shift year to year, so confirm on official sites before booking.
The quick-reference calendar
| Month | Headline events | Best for |
|---|---|---|
| January | J.P. Morgan Healthcare Conference, Biotech Showcase (San Francisco) | Fundraising, investor meetings, setting the year’s tone |
| February | BIO CEO & Investor Conference; SCOPE Summit | Investor relations; clinical operations |
| March | East-West BioPharma Summit; AGBT; Advanced Therapies Week | Cross-border partnering; genomics; cell and gene therapy |
| April | AACR Annual Meeting; World Vaccine Congress | Early oncology science; vaccines |
| May | ASGCT; TIDES; BIO-Europe Spring | Cell and gene therapy; oligonucleotides; European partnering |
| June | BIO International (San Diego); ASCO; EHA; DIA | Global partnering; pivotal oncology data; regulatory |
| July | BIO Asia-Taiwan (Taipei) | Asian partnering and market access |
| September | ESMO Congress; RAPS Convergence | European oncology data; regulatory affairs |
| October | HLTH (Las Vegas); ISPE; Cell & Gene Meeting on the Mesa | Digital health; manufacturing; cell and gene therapy |
| November | BIO-Europe (Cologne); China Healthcare Summit; SITC | European partnering; China dealmaking; immuno-oncology |
| December | ASH Annual Meeting; San Antonio Breast Cancer Symposium | Blood cancers, cell and gene therapy; breast cancer data |
Q1: the year opens loud (January to March)
The calendar starts at full volume. The J.P. Morgan Healthcare Conference week in January is the industry’s unofficial opening ceremony, concentrating investors and management teams in San Francisco and setting the tone for the year’s financing and dealmaking. February brings the BIO CEO & Investor Conference and the clinical-operations-focused SCOPE Summit. March opens the cross-border and modality season, with the East-West BioPharma Summit, the genomics-focused AGBT meeting, and Advanced Therapies Week for the cell and gene crowd. If January is about money, Q1 as a whole is about setting your relationships and priorities for the year.
Q2: the data and partnering peak (April to June)
Spring is the densest, highest-stakes stretch of the year. AACR in April kicks off the oncology data season with earlier-stage science. May brings the modality meetings, ASGCT for cell and gene therapy and TIDES for oligonucleotides and peptides, plus BIO-Europe Spring. Then June delivers the double peak: the BIO International Convention, the year’s biggest partnering event, in the same window as ASCO, the year’s biggest clinical oncology catalyst, with EHA and the DIA regulatory meeting alongside. Q2 is where the year’s science and dealmaking come to a head; it is the stretch most worth planning carefully.
Q3: the summer lull and the Asian swing (July to September)
Summer quiets down, which makes it a good time to do the follow-up work from the spring rather than chase more events. BIO Asia-Taiwan in July anchors the Asian partnering calendar. Things pick back up in September with the ESMO Congress, Europe’s major oncology catalyst, and RAPS Convergence for regulatory professionals. Use the lull; the people you want to reach are less frantic, and it is the ideal window to prepare for a strong autumn.
Q4: the strong finish (October to December)
The year ends on a high note. October brings HLTH, the big digital-health convergence event, along with manufacturing meetings like ISPE and the cell-and-gene Meeting on the Mesa. November is a partnering peak, with BIO-Europe in Cologne and the China Healthcare Summit, plus SITC for immuno-oncology. And December closes the year with ASH, the definitive hematology meeting and a major catalyst for blood cancers and advanced therapies, alongside the San Antonio Breast Cancer Symposium. A strong Q4 sets up the relationships you will carry into next January’s JPM.
How to use the calendar
Do not try to attend everything, that way lies burnout and a blown budget. Instead, pick one or two anchor events that match your primary goal, add the single best modality or regional event for your specific program, and treat the rest as optional or as something to follow from your desk. The calendar is a menu, not a checklist, and the companies that get the most from it are the ones that choose deliberately.
How investors use the conference calendar
The conference calendar is not just a travel planner; for investors it doubles as a catalyst calendar, a map of when market-moving information is likely to arrive. Because the scientific congresses are where pivotal data lands, and because the financing events cluster fundraising and dealmaking into predictable windows, the calendar lets investors anticipate when specific programs and companies could see big moves. A hematology-focused company, for instance, often has its most important data moment in December at the big blood-cancer meeting; an oncology company frequently peaks around the late-spring clinical congress. Sophisticated investors position around these windows, studying the abstracts when they drop, forming a view on whether the coming data will beat or miss expectations, and watching how the market reacts. You do not have to be an investor to use this lens. Anyone in the industry benefits from knowing that the calendar telegraphs when news is coming, which helps with everything from timing your own announcements to understanding why a competitor’s stock just moved. The other practical decision the calendar forces is attend-versus-follow: you cannot be everywhere, so decide which events justify showing up in person, usually the ones matched to your specific goals, and which you will simply track from your desk through abstracts and coverage. Most people over-attend and under-follow; a smarter split is to physically attend only where your presence changes an outcome, and to follow the rest remotely, capturing ninety percent of the informational value at a fraction of the cost and exhaustion.
Attend in person or follow remotely?
One practical shift worth knowing: many major events now offer virtual access or robust remote coverage, which changes the attend-or-not calculation. For events where your physical presence changes an outcome, partnering meetings you need to take face to face, receptions where relationships get built, going in person is worth the cost. For events you attend mainly to absorb information, following remotely through released abstracts, live coverage, and post-event analysis captures most of the value at a fraction of the cost and none of the travel exhaustion. The smartest approach is a deliberate split: physically attend the two or three events matched to your specific goals, and follow the rest of the calendar from your desk. Most people over-attend out of habit and fear of missing out; a disciplined attend-versus-follow split frees up budget and energy for the events that genuinely matter.
Do not overlook the specialty events
The headline events anchor the year, but some of the highest-value meetings for a given company are the smaller, specialty gatherings that do not make every calendar: a focused meeting in your exact modality, a regional showcase in a hub you care about, or a niche congress where the specialists in your field actually gather. These smaller events often deliver more concentrated value than the mega-conferences precisely because everyone in the room shares your focus. When you plan your year, do not just fill it with the biggest names; deliberately seek out the one or two specialty events where your particular science, disease area, or region is the whole point. A small room full of exactly the right people frequently beats a giant hall where your niche is a rounding error.
To build your own version of this calendar, filtered to the events that actually fit your goals, use the BioMed Nexus conferences directory, which tracks every major 2026 event by category and region. And to stay on top of the data and deals coming out of each event as the year unfolds, the daily brief follows the calendar in real time.
Frequently asked questions
What are the biggest biotech conferences in 2026?
The marquee events are the J.P. Morgan Healthcare Conference in January, the BIO International Convention in June, and the major oncology congresses AACR (April), ASCO (June) and ASH (December). HLTH is the largest digital-health event and BIO-Europe is Europe's biggest partnering meeting.
When is the busiest month for biotech conferences?
June is the densest, highest-stakes month, combining the BIO International Convention, the ASCO oncology meeting, the EHA hematology congress and the DIA regulatory meeting. January's JPM week is the other major peak, anchoring the year's fundraising and dealmaking.
How should I choose which biotech conferences to attend?
Pick one or two anchor events matched to your primary goal, whether fundraising, partnering, scientific data or manufacturing, then add the single best modality or regional event for your specific program. Treat the rest as optional or something to follow remotely rather than attending everything.
